Table 2.

Data related to demographic characteristics, treatment, histopathological evaluation, and follow-up of the patients

Gender	Female	5 (33.3%)
	Male	10 (66.7%)
Age at diagnosis	(years)	52.45 (29.52–72.13)
Stage	I	3 (20%)
	II	1 (6.7%)
	III	11 (73.3%)
	IV	0
Localization	Right	7 (46.7%)
	Left	8 (53.3%)
Hormonal Activity	No	11 (73.3%)
	Yes	4 (26.7%)
	• Cortisole	1 (6.7%)
	• Cortisole + DHEAS	3 (20%)
Surgery	Open	12 (80%)
	Laparoscopic	3 (20%)
Adrenal/En bloc	Adrenalectomy	6 (40%)
	En bloc	9 (60%)
Resection	Rx	2 (13.3%)
	R0	7 (46.7%)
	R1	4 (26.7%)
	R2	2 (13.3%)
Mitotic Activity	High	4 (26.7%)
	Low	1 (6.7%)
Necrosis	Yes	9 (60%)
	No	6 (40%)
Ki67	High	7 (77.8%)
	Low	2 (22.2%)
Treatment	None	7 (46.7%)
	Mitotan	3 (20%)
	Mitotane+RT	2 (13.3%)
	Mitotane+Systemic CT	2 (13.3%)
	RT+Systemic CT	1 (6.7%)
	Ketoconazole	2 (13.3%)
Recurrence and Metastasis	Development of recurrence	7 (46.7%)
	Recurrent operation	3 (20%)
	Time to recurrence	8 (2–24) mos
	Development of metastasis	6 (40%)
	Metastasectomy	2 (13.3%)

DHEAS: dehydroepiandrosteron sulphate; RT: radiotherapy; CT: chemotherapy